Ulotaront, a Trace Amine-Associated Receptor 1/Serotonin 5-HT1A Agonist, in Patients With Parkinson Disease Psychosis: A Pilot Study
Discussion
In this exploratory pilot study, ulotaront may decrease PDP symptoms without worsening motor function, particularly in patients with cognitive impairment.
Trial Registration Information
ClinicalTrials.gov identifier: NCT02969369; submitted: November 17, 2016; study start date: December 31, 2016.
Classification of Evidence
This Class II study was an exploratory pilot study that was underpowered to detect a statistically significant difference between ulotaront and placebo in the treatment of patients with Parkinson disease psychosis without worsening motor function.
Source: Neurology Clinical Practice - Category: Neurology Authors: Isaacson, S. H., Goldstein, M., Pahwa, R., Singer, C., Klos, K., Pucci, M., Zhang, Y., Crandall, D., Koblan, K. S., Navia, B., for the Parkinson's Psychosis TAAR1 Study Group Tags: Class II Research Article Source Type: research
More News: Brain | Men | Neurology | Parkinson's Disease | Schizophrenia | Sleep Disorders | Sleep Medicine | Statistics | Study